Effectiveness of treatment for localized prostate cancer assessed in Norway

02

Oct 2019

In August 2019, the Norwegian Institute of Public Health (NIPH) has released a health technology assessment report regarding the effectiveness of treatment for localized prostate cancer. This assessment was initially commissioned to NIPH by the Centre for joint decision-making (Samvalgssenteret), which provides patients with relevant and reliable information about a diagnosis and available treatment options. The main objective of the report was to summarize the findings regarding the effectiveness of relevant treatment for localized prostate cancer.

The following results were obtained by NIPH:

  • The effectiveness of the comparison of the following methods is unknown due to the lack of studies:
    • Radical prostatectomy compared to observation;
    • Low-dose-rate brachytherapy compared to observation;
    • Watchful waiting compared to low-dose-rate brachytherapy;
    • Watchful waiting compared to observation;
  • Radical prostatectomy probably improves survival at 10-12 years as compared with watchful waiting, but it is uncertain if the difference is maintained at even longer-term follow-up
  • There is little or no difference in survival after radical prostatectomy compared to low-dose-rate brachytherapy;
  • There is little or no difference in five-year cancer-free survival when comparing surgery with adjuvant radiotherapy with surgery alone, but adjuvant radiotherapy may improve ten-year survival.

See the full health technology assessment report in Norwegian here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

28

Jul 2021

On July 01, 2021, NHS England published an update of the Specialized Services Policy Pipeline (covering March 21, 2021 - June 21, 2021). One new Clinical Commissioning Policy related to radiotherapy was published. Three new policies were added to the work program; however, all related to pharmaceuticals only. The status of ongoing policies was updated as well.

Read more

26

Jul 2021

The revised EBM (German Uniform Evaluation Standard) catalog came into force on July 1, 2021. Three biomarker tests in breast cancer, a number of services related to cryopreservation of egg and sperm cells in young cancer patients, new services dedicated to prenatal testing of the fetal rhesus factor, services concerning the delivery of brachytherapy in prostate cancer were introduced.

Read more

16

Jul 2021

In June 2021, the National Institute for Health Research (NIHR) in England released six MedTech-related reports in its Health Technology Assessment (HTA) Journal, which concerned tibial nerve stimulation for urinary incontinence treatment, imaging in ophthalmology, in-vitro diagnostics, and eHealth. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS, and informs National Institute for Health and Care Excellence (NICE) guidance.

Read more

06

Jul 2021

In June 2021, the National Institute for Health and Care Excellence (NICE) published two new Interventional Procedure Guidance (laser lithotripsy for difficult-to-treat bile duct stones and percutaneous insertion of a closure device to repair a paravalvular leak around a replaced mitral or aortic valve), one new Medical Technologies Guidance (Plus Sutures for preventing surgical site infection), and four new Medtech Innovation Briefings (RapidAI for analyzing CT/MRI brain scans, WoundExpress, Magtrace and Sentimag, and SYNE-COV). Also, four clinical guidelines were updated, and two new published.

Read more

05

Jul 2021

On July 1, 2021, the updated version of the Swiss Services Ordinance (KLV/OPre) came into force. The changes concern the List of explicitly evaluated services (Annex 1 of KLV/OPre), the List of medical aids (Annex 2 of KLV/OPre), and the List of Analyses (Annex 3 of KLV/OPre).

Read more